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Purpose: Uveal melanoma is the most common intraocular primary tumor, involving iris, ciliary body and choroid. More
than 90% of the patients develop hepatic metastasis with an average survival time of 7 months. We have used formalin
fixed paraffin embedded sections to validate the presence of monosomy 3, an accurate predictor of metastasis, chromosome
8 isochromosome (8q22), and 1p36 deletion. This study also tested the presence of oncomirs in uveal melanoma samples
by microRNA (miRNA) expression profiling.
Methods: Chromogenic in situ hybridization (CISH) was performed in formalin fixed, paraffin embedded sections of
uveal melanoma to analyze chromosome 1, 3, and 8 aberrations (n=60). MicroRNA (miRNA) expression profiling was
done on paraffin sections of invasive tumor with liver metastasis (n=1) and non invasive tumor (n=1) in biological
duplicates. Samples for miRNA expression profiling were identified based on case registry and the harboring of monosomy
3 by CISH.
Results:  A  significant  correlation  (p=0.05)  between  metastasizing  and  non-metastasizing  melanoma  harboring
chromosomal aberrations- monosomy3, c-myc, and 1p36 was observed by Pearson’s correlation. A significant correlation
was observed in monosomy 3 and 1p36 positive cases in the tumor samples (p=0.039). No significance was observed
between monosomy 3 and c-myc positive cases. No significance (p=0.096) was observed between c-myc amplification
and trisomy (extra whole chromosome 8). MicroRNA expression profiling revealed the presence of 19 miRNAs expressed
in non-metastasizing melanoma and absent in metastasizing melanoma. Eleven miRNAs were found to be expressed in
metastasizing melanoma and absent in non-metastasizing melanoma. Genes targeted by the miRNAs were found to be
present in chromosomal regions 8p22, 13q, and 17p but were often found to be deleted.
Aneuploidy  in  cancer  has  been  studied  widely  by
cytogenetic techniques to identify molecular determinants in
metastasis. Uveal melanoma is a common primary intraocular
tumor, originating from melanocytes and metastasizes to the
liver in 95% patients leading to death within 2-14 months
[1]. This makes uveal melanoma an attractive model to study
the  indicators  of  tumor  metastasis.  Tumor  related  factors
include extra ocular extension, tumor size, anterior tumor
location, increased tumor invasiveness, tumor pigmentation,
microvascular patterns, microvascular density and cell type.
Uveal melanoma is known to carry deletions in 3p25, 3q24,
all of chromosome3, 1p36, 6q23, 9p21-9p23, 13q14, 13q12.3-
q13, and 17p13. Amplification observed in 1q, 16p, 20q , 22q
[2,3], 8q22, and an extra chromosome 8 [4]. Conventional
cytogenetics  including  fluorescent  in  situ  hybridization
(FISH) and Chromogenic in situ hybridization (CISH) have
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demonstrated that non-random chromosomal abnormalities,
the loss of chromosome 3, and amplification of 8q are related
to high mortality [3] and the loss of 1p36 in metastasizing
tumors  is  associated  with  concurrent  monosomy  3  [5].
Aberrations in 6p and 6q regions have been observed to be
involved  in  tumor  initiation  and  development  rather  than
tumor  progression  [6].  Sandinha  et  al.  [7]  has  identified
monosomy 3 in metastasizing melanoma by CISH.
CISH is being used to study many cancers as a molecular
and cytogenetic tool to assess tumorogenicity, becoming an
important component in molecular diagnostics and research
studies. This technique is generally monochromatic, allowing
a  single  target  sequence  to  be  detected  using  alkaline
phosphatase/peroxidase  reactions.  The  signals  and  tissue
morphology can be simultaneously detected by bright field
microscopy. Recent advances in this technique has led to dual
color  CISH,  which  has  enabled  aberrations  in  breast
carcinoma to be studied by detection of biotin and digoxigenin
labeled probes simultaneously within the nuclei, resulting in
green and red chromogenic signals. A ratio of centromere to
other chromosomal regions is studied to visualize relevant
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Conclusions: This technique can be applied to routine pathology using archival specimens to identify patients with
monosomy 3. We were able to perform CISH in all the cases except the heavily pigmented tumors, where dots were
observed but were not assessed. Initial studies on microRNA have revealed their role as oncomirs in both metastasizing
and non-metastasizing melanomas. Further studies may provide insights into their role in tumor progression and facilitate
metastatic phenotype analysis.diagnostic translocations in the tumor sample, resulting in
direct correlation of genotypic and phenotypic characteristics.
Human epidermal growth factor receptor-2 amplification
analysis  by  CISH  in  breast  cancer  has  revealed  highly
reproducible  results  concordant  with  Fluorescent  in  situ
hybridization  and  immunohistochemistry  and  as  a  viable
alternative to the other techniques [8,9]. Cytological smears
are also found to be good source to study Her-2/neu status in
breast cancer by CISH. Other cancers such as squamous cell
esophageal carcinoma [10] and non-small cell lung carcinoma
[11]  have  been  studied  for  their  respective  chromosomal
aberration in individual cancer by CISH.
Advent of gene expression and miRNA profiling in uveal
melanoma has led to the identification of molecular markers,
that classify tumors as Class I (low metastatic risk) and Class
II (high metastatic risk). Studies on gene expression profiling
have  identified  downregulated  genes  in  chromosome  3p
region [12] and upregulated regions in chromosome 8q [13].
LZTS1, a tumor suppressor gene was found to be deleted in
8p22 region [14]. A study reports amplification of DDEF1
located  in  8q24  [15].  miRNA  expression  profiling  has
identified significant miRNA discriminators in class I and
Class  II  and  specific  miRNA  associated  with  metastatic
priority [16].
METHODS
Study population: The study was reviewed and approved by
the  local  ethics  committee  the  study  conformed  to  the
generally accepted principles of research in accordance with
the Helsinki Declaration. Archival specimens of choroidal
melanoma were identified from the patient medical records
from 1994-2009 (15 years).The tumors were categorized as
invasive (with liver metastasis), non-invasive, intrascleral, or
extrascleral. Patients with liver metastasis were confirmed by
case records including imaging and liver tests. All tissues had
been previously fixed in neutral buffered formalin for 12-24
h. All tumor slides stained with hematoxylin and eosin were
examined  for  invasion  of  choroid,  optic  nerve,  intra  and
extrascleral extension, necrosis, and pigmentation after which
1-2 representative tumor tissue blocks were selected. A total
of 60 tumor samples and 11 retinas were taken for use as
internal controls. For miRNA expression analysis, 2x20 µm
formalin fixed, paraffin embedded sections were taken from
a metastasizing tumor and non-metastasizing case identified
from the case registry. Our CISH studies confirmed that the
selected tumor sections harbored monosomy 3 aberration, in
the  metastasizing  case  and  no  aberration  in  the  non  -
metastasizing case.
Centromeric and locus specific probes: All probes used were
purchased from Zymed Laboratories (San Francisco, CA).
Unlike  traditional  cytogenetic  DNA  probes  which  require
repetitive specific blocking; these probes were created by
eliminating  repetitive  sequences  using  subtraction  probe
technology. They are doublestranded and labeled with biotin/
digoxigenin (DIG). Centromeric probes labeled with biotin
have been used to study monosomy in chromosome 3 and
extra chromosome 8 (trisomy). Locus-specific probes used to
study chromosome 8–c-myc amplification and 1p36 deletion
were labeled with digoxigenin. Centromeric probe 18 was
employed as the control probe as aneuploidy in chromosome
18 was not observed in choroidal melanoma.
Tissue section preparation: Four to five μm tissue sections
were placed on Super Frost Plus positively-charged slides and
baked at 60 °C for 6-18 h. The slides were then deparaffinized
in 100% xylene, rehydrated, and cleared in a graded series of
methanol from 100% -60% to water.
Depigmentation  was  performed  for  moderately
pigmented  and  heavily  pigmented  sections.  Moderately
pigmented  tumors  were  depigmented  in  0.25%  potassium
permanganate and 5% oxalic acid. Heavily pigmented tumors
were depigmented in 3.0% (vol/vol) hydrogen peroxide and
1.0% (wt/vol) disodium hydrogen phosphate, 18 h at room
temperature  overnight.  Sections  were  subjected  to  heat
pretreatment in TRIS –EDTA, pH 8.0 at 98 °C for 15 min.
After rapid cooling in water for few seconds, a PBS wash was
performed. Tissues were incubated with pepsin, an enzyme
pretreatment  reagent  (Zymed  Laboratories)  for  8-10  min
washed in PBS followed by dehydration in a graded series of
alcohol and air dried for 15-20 min.
Denaturation and hybridization of probe: Probe in formamide
hybridization mix was added to the tissue sections as per the
tissue size. Cover slips were sealed over the tissue with a
rubber solution to prevent evaporation during the subsequent
denaturation step at 95 ºC for 6 min was carried out in a
gradient in situ PCR thermal cycler followed by overnight for
(18 h) hybridization.
Immunohistochemical and signal detection of probe: Partially
bound and unbound probes were removed by 0.5× SSC wash
at  room  temperature  for  5  min  and  75  ºC  for  5  min.
Endogenous  peroxidase  was  removed  by  submerging  the
slides in 3% hydrogen peroxidase in methanol. Slides were
incubated with CAS block reagent (zymed for 10 min). For
locus specific probes, slides were incubated for 1 h in mouse
anti-digoxigenin  antibody  followed  by  rinse  in  PBS
containing 0.025% Tween-20. The slides were then incubated
with goat anti-mouse HRP polymer conjugate for 1 h and later
rinsed in PBS-Tween. Tissues hybridized with centromeric
probes were incubated with HRP-streptavidin for 1 h. Slides
were further incubated with DAB substrate for 30 min. The
sections were rinsed in tap water and counterstained with
haematoxylin for a few seconds. The slides were then washed
in running tap water, dehydrated in graded series of methanol
and mounted with histomount.
Analysis – quantification of hybridization signals: The tissue
sections were examined by light microscopy using an oil
immersion lens (magnification 1000×). CISH results were
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to be reproducible. A minimum of 100 nuclei were counted.
The chromosomal aberrations were assessed by using both
chromosomal  index  and  signal  distribution  (SD).
Chromosomal index is calculated by dividing the number of
hybridization sites by the number of nuclei counted, this gives
the average chromosome number. The chromosome index
(CI), which gives an average chromosome copy number, was
calculated by dividing the total number of hybridization spots
counted by the total number of nuclei counted [7].
Chromosome loss is defined as CI<3 SD from the mean
for  retina  (normal  tissue  ),  for  chromosomes  1  and  3.
Chromosome 8 amplification was defined as disomy in case
of two dots, extra chromosome - trisomy and amplified (4-8
copies).  SD  is  defined  as  the  %  of  nuclei  with  only  one
hybridization in case of chromosomes 1 and 3. The tumor
TABLE 1. SUMMARY OF SIGNAL DISTRIBUTION FOR CHROMOSOME 3, 8, AND 1.
Probe <15% 30% 40% 50% 60% 70%
a. Monosomy3 35 8 3 3 - -
b. c-myc-8 43 1 - - 2 3
c. Trisomy-8 47 - - 1 1 -
d. Deletion-1p36 44 1 - 1 - 3
The first column a-d represents the chromosomal aberration observed in uveal melanoma samples (n=49) in the respective
percentages, <15% was not taken into account for the respective aberration. Hybridization site >30% was taken as positive for
signal distribution analysis.
Figure 1. Chromogenic in situ hybridization for chromosome 3 and 8q22. A: Invasive melanoma, hybridized with chromosome 3 showing
single copy in all the cells. B: Non-metastasising melanoma, hybridized with chromosome 3 showing two copies in most of the cells. C:
Normal retina hybridized with chromosome 3 showing two copies in all the cells. D: Invasive melanoma, hybridized with chromosome 8q22
showing two copies in most of the cells. E: Non-metastasising melanoma, hybridized with chromosome 8q22 showing two copies in most of
the cells. F: Normal retina hybridized with chromosome 8q22 showing two copies in all the cells.
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be regarded as monosomy or deleted [7].
MicroRNA isolation and expression analysis:
Sample  processing  and  RNA  extraction—Sections
(2x20 µm) of metastasizing melanoma and non metastasizing
melanoma were selected and deparrafinized in xylene and
washed  with  ethanol  and  subjected  to  overnight  protease
digestion.  Total  RNA  was  isolated  using  TRI-Reagent
(Ambion, Austin,TX). RNA concentration and purity was
quantified  using  Nanodrop  (Nanodrop  Santa  Clara,  CA)
spectrophotometer by nanodrop ribogreen assay and quality
of total RNA was determined on an Agilent (Agilent, Santa
Clara, CA) bioanalyzer.
Agilent arrays- hybridization and detection—Human
miRNA V2 8x15k Agilent arrays which represents 723 human
and 76 human viral miRNAs were used for miRNA analysis.
Total RNA underwent phosphatase treatment. The 3’end of
dephosphorylated RNA was ligated with one molecule of (3-
pCp), cyanine 3-cytidine bisphosphate (pCp) as this reagent
selectively  labels  and  hybridizes  mature  miRNAs,  with
greater than 30% efficiency. Hybridization cocktail was added
to  the  arrays  and  hybridization  was  performed  in  the
hybridization oven set at 55 ºC for 20 h. The microarrays were
washed using Agilent wash buffer. Scanning and extraction
was performed using Agilent feature extraction software. The
study was done in biological replicates. The intensities and
background subtracted were taken from the Raw Data file
generated from Agilent Feature Extraction software (Aligent).
The Sum of background-subtracted signals for each repeated
miRNA was calculated. The sum of background-subtracted
signal for each of repeated miRNA was log transformed to log
base 2. Cut off used was greater than 1 (Log Trasnformed
value) in metastatic and less than 1(Log Trasnformed value)
in non- metastatic and vice versa.
RESULTS
Assessment of chromosomal index and signal distribution: In
situ hybridization for chromosome 1p36, 3, 8, and 18 was
successfully performed for 49 samples, 11 samples were not
taken into account due to heavy pigmentation. Hybridization
signals obtained as a result of addition of locus specific and
Figure 2. Chromosome in situ hybridization for aberrations in chromosome 8 (extra whole chromosome and chromosome 1 (1p36). A: Invasive
melanoma, hybridized with chromosome 8 showing trisomy in few cells and two copies in most of the cells. B: Non-metastasising melanoma,
hybridized with chromosome 8 showing two copies in most of the cells. C: Normal retina hybridized with chromosome 8 showing two copies
in all the cells. D: Invasive melanoma, hybridized with chromosome 1p36 showing one copy in all the cells. E: Non-metastasizing melanoma,
hybridized with chromosome 1p36 showing two copies in most of the cells. F: Normal retina hybridized with chromosome 1p36 showing two
copies in all the cells.
Molecular Vision 2009; 15:2146-2154 <http://www.molvis.org/molvis/v15/a231> © 2009 Molecular Vision
2149centromeric  probes  were  analyzed  on  the  basis  of
chromosomal index and signal distribution. For each tumor
section (n=49) number of signal spots per nucleus was counted
for 100 nuclei and the pathologist was masked to the outcome
of patient. Overlapping nuclei and over digested cells with
poor  quality  hybridization  signal  was  excluded.  For
chromosome 1p36 and 3 the mean CI for retina was 1.56 and
1.53. A tumor was defined as monosomic for chromosome 3
if its CI was less than 3SD from the mean. Signal distribution
is the percentage of nuclei with one hybridization site greater
than 30% of nuclei counted. This analysis was performed as
per criteria taken in [17]. Nuclei carrying <15% of hybridized
spots  was  not  considered  to  be  harboring  the  respective
chromosomal aberration (Table 1). Liver metastatic case of
choroidal melanoma hybridized with chromosome 3 showed
a single copy in nearly all the cells, whereas in noninvasive
melanoma and retina showed two copies (Figure 1). Other
examples of metastatic melanoma, choroidal melanoma and
normal retina hybridized with 1p36 are shown in (Figure 2D-
F ), 8q22 (Figure 1D-F), whole chromosome 8 (Figure 2A-C),
and chromosome 18 (Figure 3A-C). 8q22 amplification in
breast carcinoma is seen as large clusters as shown in Figure
3D.
Statistical  significance:  A  significant  correlation(p=0.05)
between  metastasizing  and  non  metastasizing  uveal
melanoma  with  respect  to  the  chromosomal  aberrations-
monosomy 3,C-myc and 1p36 was observed by Pearson’s
correlation. There exists a significant correlation between the
two classes with respect to the balanced expression of the
chromosomes.  A  significant  correlation  was  observed  in
monosomy and 1p36 positive cases in the tumor samples
(p=0.039). No significance was observed between monosomy
3 and c-myc positive cases. No significance was observed
between  c-myc  amplification  and  trisomy  (extra  whole
chromosome 8; p=0.096).
MicroRNA expression analysis: The data discussed in this
publication have been deposited in NCBI's Gene Expression
Omnibus  [18]  and  are  accessible  through  GEO  Series
accession number GSE17037. Nineteen miRNAs were found
to be expressed in non metastatic tumor and unexpressed in
metastatic tumors. 11 miRNAs were found to be expressed in
metastatic tumors and unexpressed in non metastatic tumor
(Table 2 and Table 3).
Figure 3. Chromogenic in situ hybridization for chromosome 18 and 8q22 amplification in breast carcinoma. A: Invasive melanoma, hybridized
with chromosome 18 showing two copies in all the cells. B: Non-metastasizing melanoma hybridized with chromosome 18 showing two
copies in most of the cells. C: Normal retina hybridized with chromosome 18 showing two copies in all the cells. D: Breast carcinoma hybridized
with chromosome 8q22 showing positive amplification (large cluster).
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.DISCUSSION
In the field of Immuno histochemistry (IHC) and FISH, it is
routine clinical practice to analyze tumor status in reference
to chromosomal aberration. IHC is applied to identify over
expression  of  proteins,  yet  it  also  involves  inter  observer
variability  and  leads  to  false  positive  results.  FISH  is  an
accurate and sensitive method to study gene amplification
studies but needs an expensive fluorescence microscope and
the signal fades in course of time. CISH is a cytogenetic study,
detecting aneuploidy in both interphase and metaphase within
a tumor section.
Interpretation difficulties were encountered occasionally
with  overlapping  nuclei  and  particulate  debris  on  slides.
Heavily  pigmented  tissues  that  were  not  completely
depigmented by either method were not taken into account
due  to  signal  interference  by  pigments.  CISH  reveals
chromosomal abnormalities in the given sample but not the
genes that are present in the deleted region. Deleted regions
are believed to harbor tumor suppressor genes. Non-random
chromosomal  abnormalities  in  uveal  melanoma  linked  to
metastatic death is yet to be established as effective clinical
predictive testing tool. Gene expression analysis identifies
deregulated genes in the given tumor samples. MicroRNAs
are endogenous molecules that play a significant role in gene
regulation.
As our aim was to analyze aberrations in chromosome 1,
3, and 8 in uveal melanoma, an in depth study on intra tumor
heterogeneity was not performed. Other cytogenetic studies
in uveal melanoma have revealed the presence of monosomy
3 in epithelioid cells and not in spindle cells. Studies on
genetic heterogeneity in uveal melanoma has been reported in
monosomy  3  in  spindle,  epithelioid  and  mixed  cell  type.
Though tumor biopsies can be used for diagnosis, prognosis,
and therapeutic decision making, a better insight in identifying
patients with high risk could be materialized by assessing
samples from several other areas of tumor by the transscleral/
transvitreal approach [45].
Studies have reported the presence of miRNAs in cell
lines,  primary  cultured  melanomas.  Worley  et.al  have
identified differentially expressed miRNAs that could act as
prognostic biomarkers of metastatic risk compared to primary
uveal melanoma with low metastatic risk [16]. They have
identified  6  miRNAs  discriminators  that  accurately  that
accurately distinguish class I (low metastatic risk) and class
II  (high  metastatic  risk).  To  our  knowledge  there  are  no
published studies on miRNA expression profiling in formalin
fixed  paraffin  embedded  sections  in  uveal  melanoma.
MicroRNAs from formalin fixed paraffin embedded sections
(FFPE)  show  reliable  expression  level  compared  to  snap
frozen  samples,  though  larger  number  of  FFPE  cells  are
required to isolate total RNA compared to snap frozen cells
[46].
We have studied miRNA expression profiling on tumors
classified as non invasive and liver metastasis as per case
registry and presence of monosomy in biological replicates.
Nineteen miRNAs were found to be expressed only in class I
tumors and not in class II and 11 miRNAs were found to be
expressed only in class II and not in class I. Similar scenario
was  observed  in  Worley  et  al  study.  Similarly  miRNA
expression is found to be lower in cancer cells compared to
normal  cells.  The  selected  tumors  were  found  to  harbor
oncomirs  in  both  choroidal  melanoma  and  metastasizing
melanoma targeting  metastatic  suppressor genes (Table 2) 
and tumor suppressor genes (Table 3).
None of the differentially expressed miRNAs in either
case were found to be located on the chromosomes which have
been proved to carry chromosomal abnormalities. Rather it
was found that the differentially expressed miRNAs bind to
3’UTR segments of genes that were often found to be deleted
in  chromosomal  regions  8p22,  13q,  and  17p  in  uveal
melanoma (Table 2 and Table 3). Prediction targets of has-
miR-196a, a metastatic suppressor gene-CASP8 observed in
neuroblastoma  cells.  Repression  of  caspase-8  reduces
metastasis without affecting the primary tumor. Martinez et
al. [46] have observed that hypermethylation and silencing of
CASP8 is correlated to glioblastoma multiforme.
Predicted target DLC1, deleted in liver cancer, is found
to act as tumor suppressor in hepatocellular and non-small cell
lung carcinoma [47]. In our target prediction study, we have
observed that miR-495 binds to 3’UTR segment of DLC1 and
metastatic  suppressor  gene  in  breast  carcinoma  call  line
M4A4  [48].  miR-18a  predicted  target  BRMS1,  a  nuclear
metastasis suppressor gene, is found to suppress experimental
metastasis  of  melanoma,  bladder  and  ovarian  carcinomas
[49].  KISS1,  a  cytoplasmic  metastasis  suppressor  gene  is
targeted by miR-497. miR-556-5p targets tumor protein P53
and  miR-19b1  targets  retinoblastoma  associated  protein.
miR-155 an upregulated miRNA in breast, lung and colon
cancer is found to be upregulated in both the tumors.
These  results  indicate  the  need  for  further  functional
studies to validate the presence of oncomirs in metastatic and
non-metastatic  uveal  melanomas  that  target  metastatic
suppressor genes and tumor suppressor genes. Identification
of these genes will explore the significant miRNAs that play
a  major  role  as  biomarkers  in  tumor  progression  and
metastasis.
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